SMA Outcome Measures Training for Physiotherapists and Occupational Therapists
As a part of the NMD4C’s clinical research work pillar, we are supporting the development and training on validated NMD outcome measures. Considering the evolving therapeutic landscape of Spinal muscular atrophy (SMA) and the need for high-quality real-world data, convening clinicians to discuss and train on nationally agreed-upon outcome measures (OM) will enhance our capacity to uncover significant disease trajectory patterns and therapy responses.
In March, we provided an opportunity for physiotherapists and occupational therapists to attend our first training session of this kind for outcome measures in SMA.
To complement this training session, we will host an English-language training on standardizing assessment practices in SMA outcome measures later in 2024, which will include the learnings from the March training session in Quebec. We will reach out to share more information on this English-language training session when details are available.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.